Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAK-ER: Palbociclib + Fulvestrant for Molecular Relapse in ER+ Breast Cancer
NCT04985266Phase 2Recruiting
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Mar 2022
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of palbociclib, fulvestrant in breast cancer, sponsored by Royal Marsden NHS Foundation Trust. Started Mar 2022; status: recruiting.
02
Drugs
palbociclibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04985266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04985266.